Trends & Investment Report: Early & Managed Access Programmes
The number of named patient requests has increased over time due to patients, advocacy groups and physicians becoming increasingly well informed on the developmental pipelines of pharma and biotechs across the world. To keep up with rising demands, pharma companies have had to invest heavily in Early Access Programmes to meet the unmet medical needs of patients who have exhausted all other roots of treatment.
Ahead of the Early and Managed Access Programmes Forum taking place this November in London, Pharma IQ have created an infographic detailing the industries outsourcing challenges and investment plans to help vendors navigate through this ever-changing market landscape.
Download our infographic to get the latest insights into:
- The level at which pharma companies are running an active programme in the next 12 months.
- The current capability of pharma companies to conduct an Early Access Programme in-house from end-to-end.
- Which aspects of Early Access Programme require the support of external solution providers.
- How much pharma companies are looking to invest into expanded and managed access programmes in the next 12-24 months.
Please note: That all fields marked with an asterisk (*) are required.